'We demonstrate the first generalizable strategy using a small molecule to selectively kill TP53 mutant cells. This molecule binds the Y220C mutant of p53 and concentrates a PLK1 inhibitor in cells harboring TP53 Y220C mutations.'
#Preprint
https://www.biorxiv.org/content/10.1101/2024.07.27.605429v1
@cyrilpedia Very interesting.
Here's to hope that it can be given to humans without significant off-target effects at therapeutic dose levels.
